Solomon Moshkevich Sells 915 Shares of Natera (NASDAQ:NTRA) Stock

Natera, Inc. (NASDAQ:NTRA) insider Solomon Moshkevich sold 915 shares of the stock in a transaction that occurred on Tuesday, March 10th. The stock was sold at an average price of $204.13, for a total value of $186,778.95. Following the sale, the insider owned 150,882 shares in the company, valued at $30,799,542.66. The trade was a 0.60% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this link.

Solomon Moshkevich also recently made the following trade(s):

• On Monday, March 2nd, Solomon Moshkevich sold 3,000 shares of Natera stock. The shares were sold at an average price of $199.85, for a total value of $599,550.00.
• On Tuesday, February 3rd, Solomon Moshkevich sold 1,639 shares of Natera stock. The shares were sold at an average price of $230.77, for a total value of $378,232.03.
• On Monday, February 2nd, Solomon Moshkevich sold 3,000 shares of Natera stock. The stock was sold at an average price of $231.44, for a total value of $694,320.00.
• On Wednesday, January 28th, Solomon Moshkevich sold 1,200 shares of Natera stock. The shares were sold at an average price of $237.66, for a total value of $285,192.00.
• On Tuesday, January 27th, Solomon Moshkevich sold 1,013 shares of Natera stock. The shares were sold at an average price of $240.53, for a total value of $243,656.89.
• On Wednesday, January 21st, Solomon Moshkevich sold 293 shares of Natera stock. The shares were sold at an average price of $235.00, for a total transaction of $68,855.00.
• On Tuesday, January 20th, Solomon Moshkevich sold 23,205 shares of Natera stock. The stock was sold at an average price of $234.74, for a total transaction of $5,447,141.70.
• On Friday, January 2nd, Solomon Moshkevich sold 2,951 shares of Natera stock. The stock was sold at an average price of $228.95, for a total transaction of $675,631.45.
• On Friday, December 12th, Solomon Moshkevich sold 4,692 shares of Natera stock. The shares were sold at an average price of $230.76, for a total transaction of $1,082,725.92.

Natera Stock Down 3.2%

Natera stock opened at $190.31 on Friday. The firm has a 50-day moving average price of $220.54 and a two-hundred day moving average price of $205.96. The firm has a market capitalization of $26.97 billion, a price-to-earnings ratio of -124.39 and a beta of 1.65. Natera, Inc. has a 52-week low of $125.38 and a 52-week high of $256.36.

Natera (NASDAQ:NTRA) last posted its earnings results on Thursday, February 26th. The medical research company reported $0.35 EPS for the quarter, topping the consensus estimate of ($0.46) by $0.81. Natera had a negative net margin of 9.03% and a negative return on equity of 15.28%. The firm had revenue of $665.50 million during the quarter, compared to analysts’ expectations of $600.68 million. During the same quarter in the prior year, the firm earned ($0.41) EPS. Research analysts expect that Natera, Inc. will post -1.49 earnings per share for the current year.

Trending Headlines about Natera

Here are the key news stories impacting Natera this week:

• Positive Sentiment: Natera announced the commercial launch of its Zenith™ Genomics rare‑disease diagnostic product, marking a new commercial offering that could expand the company’s addressable market for clinical whole‑genome testing. Natera Announces Commercial Launch of Zenith™ Genomics for Rare Disease Diagnosis
• Positive Sentiment: MyOme debuted the Zenith™ portfolio with Natera and launched long‑read methylation analysis at ACMG 2026 — a technology/commercial collaboration that could broaden Natera’s diagnostic capabilities (epigenetic and long‑read WGS) and improve clinical utility over time. MyOme Debuts Zenith™ Portfolio with Natera and Launches Long-Read Methylation Analysis at ACMG 2026
• Positive Sentiment: Market reaction in the space: competing specialist GeneDx reported a share drop after Natera’s launch, suggesting investors see the new product as competitive and potentially share‑grabbing in the rare‑disease testing market. This is an indirect validation of the commercial opportunity. GeneDx stock falls as Natera launches competing rare disease test
• Neutral Sentiment: Natera presented at the Leerink Global Healthcare Conference (transcript available). The presentation provides management commentary on product adoption, reimbursement and growth drivers — useful for modeling but not an immediate market catalyst on its own. Natera, Inc. (NTRA) Presents at Leerink Global Healthcare Conference 2026 Transcript
• Negative Sentiment: Insider selling: CEO Steven Chapman sold ~5,623 shares and other senior insiders (CFO Michael Brophy, John Fesko, Solomon Moshkevich) also sold shares on the same date. Multiple concurrent insider sales are weighing on sentiment and likely contributed to today’s downward pressure. SEC Form 4 — CEO Sale

Wall Street Analysts Forecast Growth

Several analysts recently commented on NTRA shares. Morgan Stanley lowered their target price on Natera from $265.00 to $250.00 and set an “overweight” rating on the stock in a research report on Tuesday, March 3rd. Wells Fargo & Company boosted their price target on Natera from $205.00 to $215.00 and gave the stock an “equal weight” rating in a research report on Friday, February 27th. UBS Group increased their price target on Natera from $218.00 to $280.00 and gave the stock a “buy” rating in a research note on Tuesday, November 18th. Zacks Research raised Natera from a “strong sell” rating to a “hold” rating in a report on Thursday, January 1st. Finally, JPMorgan Chase & Co. lifted their price objective on shares of Natera from $250.00 to $260.00 and gave the company an “overweight” rating in a research note on Monday, December 15th. One research analyst has rated the stock with a Strong Buy rating, thirteen have issued a Buy rating, three have assigned a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, Natera presently has an average rating of “Moderate Buy” and a consensus target price of $253.47.

Institutional Investors Weigh In On Natera

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Mozayyx Management LLC bought a new position in Natera during the 4th quarter valued at $309,000. Caitong International Asset Management Co. Ltd acquired a new position in shares of Natera during the 4th quarter valued at $175,000. Reflection Asset Management bought a new stake in shares of Natera in the 4th quarter worth $29,000. Tobam raised its stake in shares of Natera by 24,935.0% in the 4th quarter. Tobam now owns 5,007 shares of the medical research company’s stock worth $1,147,000 after buying an additional 4,987 shares in the last quarter. Finally, Groupama Asset Managment lifted its holdings in shares of Natera by 19.5% in the fourth quarter. Groupama Asset Managment now owns 92,256 shares of the medical research company’s stock valued at $21,135,000 after buying an additional 15,072 shares during the period. Institutional investors own 99.90% of the company’s stock.

Natera Company Profile

Natera is a global diagnostics company that develops and commercializes cell-free DNA and other genetic testing technologies for clinical applications. The company focuses on three principal areas: reproductive health (including non-invasive prenatal testing and carrier screening), oncology (tumor-informed assays for minimal residual disease and recurrence monitoring), and organ transplantation (cell-free DNA tests to detect allograft injury). Natera combines laboratory testing, proprietary bioinformatics, and clinical reporting to deliver personalized genetic information to clinicians and patients.

Key product offerings include Panorama, a non-invasive prenatal test that screens for fetal chromosomal abnormalities and select single-gene conditions; Horizon carrier screening for inherited conditions; Signatera, a personalized, tumor-informed assay used for detecting minimal residual disease and monitoring treatment response in cancer patients; and Prospera, a donor-derived cell-free DNA test used to assess the risk of organ rejection.